Patents by Inventor Jiann-Shiun Lai

Jiann-Shiun Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11236154
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: February 1, 2022
    Assignee: OBI PHARMA INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen
  • Publication number: 20210284719
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Application
    Filed: July 31, 2017
    Publication date: September 16, 2021
    Inventors: Cheng-Der Tony YU, Woan Eng CHAN, Shu-Yu LEE, Jiann-Shiun LAI, I-Ju CHEN
  • Publication number: 20210228732
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnositcs. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Application
    Filed: January 27, 2021
    Publication date: July 29, 2021
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
  • Patent number: 11041017
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 22, 2021
    Assignee: OBI Pharma, Inc.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
  • Patent number: 11000601
    Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 11, 2021
    Assignee: OBI PHARMA, INC.
    Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
  • Publication number: 20210113711
    Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju CHEN, Yi-Chien Tsai, Kai-Chuan Chen
  • Patent number: 10980894
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: April 20, 2021
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
  • Publication number: 20210093733
    Abstract: Antibody drug conjugates (ADC's) comprising a drug moiety/payload conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Application
    Filed: August 30, 2020
    Publication date: April 1, 2021
    Inventors: Michael Nientse CHANG, Ming-Tain LAI, Jiann-Shiun LAI, Yi-Chien TSAI, I-Ju CHEN, Wan-Fen LI, Kai-Chuan CHEN, Teng-Yi HUANG, Shu-Yi LIN
  • Patent number: 10815307
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 27, 2020
    Assignee: OBI Pharma Inc.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai
  • Patent number: 10781266
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 22, 2020
    Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Po-Yin Lin, Ya-Wei Tsai, Chao-Yang Huang, Ying-Yung Lok, Chung-Hsiun Wu, Hsien-Yu Tsai, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
  • Publication number: 20200138967
    Abstract: The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies; alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein; including human Siglec-9 or a mammalian Siglec-9; wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.
    Type: Application
    Filed: October 2, 2019
    Publication date: May 7, 2020
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, Yi-Chien TSAI
  • Publication number: 20200048334
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 13, 2020
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN
  • Publication number: 20190389963
    Abstract: The present disclosure relates to treatment of cancer patients with anti-Globo series antigens (Globo H and SSEA-4) antibodies in combination with anti-negative immune check point antibody to rescue the inhibited T cell activity.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 26, 2019
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, Yi-Chien TSAI, Jo-Fan CHANG
  • Patent number: 10501532
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 10, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen
  • Publication number: 20190322762
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Application
    Filed: March 19, 2018
    Publication date: October 24, 2019
    Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: SHIH-CHONG TSAI, TA-TUNG YUAN, SHIH-CHI TSENG, JIANN-SHIUN LAI, CHIA-CHENG WU, PO-YIN LIN, YA-WEI TSAI, CHAO-YANG HUANG, YING-YUNG LOK, CHUNG-HSIUN WU, HSIEN-YU TSAI, NENG-YAO SHIH, KO-JIUNN LIU, LI-TZONG CHEN
  • Publication number: 20180339061
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
    Type: Application
    Filed: June 1, 2018
    Publication date: November 29, 2018
    Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
  • Patent number: 10138300
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: November 27, 2018
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Jiann-Shiun Lai, Li-Shuang Ai, Yan-Da Lai, Yen-Yu Wu, Yi-San Tsai, Yi-Jiue Tsai, Juo-Yu Huang, Cheng-Chou Yu, Chuan-Lung Hsu, Chien-Tsun Kuan, Szu-Liang Lai, Li-Ya Wang
  • Publication number: 20180193481
    Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testicle cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
  • Publication number: 20180186884
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.
    Type: Application
    Filed: July 3, 2017
    Publication date: July 5, 2018
    Inventors: JIANN-SHIUN LAI, Li-Shuang Ai, Yan-Da Lai, Yen-Yu Wu, Yi-San Tsai, Yi-Jiue Tsai, Juo-Yu Huang, Cheng-Chou Yu, Chuan-Lung Hsu, Chien-Tsun Kuan, Szu-Liang Lai, Li-Ya Wang
  • Publication number: 20180134799
    Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 17, 2018
    Inventors: Cheng-Der Tony YU, Jiann-Shiun Lai, I-Ju Chen, Cheng-Chi Wang, Yi-Chien Tsai